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Abstract
Background: The efficacy and safety of rituximab-based chemotherapy (R-chemo), the standard regimen for
patients with diffuse large B-cell lymphoma (DLBCL), which is more common in Asia than in Western countries, are
well confirmed in randomized controlled trials (RCTs). However, the safety and effectiveness of R-chemo in patients
who are largely excluded from RCTs have not been well characterized. This real-world study investigated the safety
and effectiveness of R-chemo as first-line treatment in Chinese patients with DLBCL.
Methods: Treatment-naive DLBCL patients who were CD20 positive and eligible to receive R-chemo were enrolled
with no specific exclusion criteria. Data collected at baseline included age, gender, disease stage, international
prognostic index (IPI), B symptoms, extranodal involvement, performance status, and medical history. In the present
study, data on safety, treatment effectiveness, and HBV infection management were collected 120 days after the
last R-chemo administration.
Results: Overall, R-chemo was well tolerated. The safety profile of R-chemo in patients with a history of heart or
liver disease was well described without any additional unexpected safety concerns. The overall response rate (ORR)
in the Chinese patients from this study was 94.2 % (complete response [CR], 55.0 %; CR unconfirmed [CRu] 18.2 %;
and partial response [PR], 20.9 %). Compared to patients with no history of disease, the CR and PR rates of patients
with a history of heart or liver disease were lower and higher, respectively; this tendency could be in part explained
by treatment interruptions in patients with heart or liver diseases. HBsAg positivity and a maximum tumor diameter
of ≥7.5 cm negatively correlated with CR + CRu, whereas age and HBsAg positivity negatively correlated with CR.
Conclusions: This study further validated the safety and effectiveness of R-chemo in Chinese patients with DLBCL.
Patients with a history of heart or liver disease may further benefit from R-chemo if preventive measures are taken
to reduce hepatic and cardiovascular toxicity. In addition to IPI and tumor diameter, HBsAg positivity could also be
a poor prognostic factor for CR in Chinese patients with DLBCL.
Trial registration: ClinicalTrials.gov #NCT01340443, April 20, 2011.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most
common form of aggressive non-Hodgkin lymphoma
(NHL), accounting for approximately 31 % of NHL
cases in Western patients [1]. In China, DLBCL is the
most common subtype of NHLs (38 %) and mature B-
cell neoplasm (54 %) [2]. Currently, rituximab plus
chemotherapy (R-chemo) remains the standard of care
for patients with DLBCL [3, 4]. The addition of rituxi-
mab to chemotherapy significantly improves outcomes
in patients with DLBCL, with a 10-year overall survival
rate of 43.5 % [5]. Numerous randomized clinical trials
(RCTs) have established the benefits of R-chemo in pa-
tients with DLBCL [5–10].
However, RCTs have limited generalizability because
extrapolation of results is limited to specific groups of
patients, as enrolled in the study following stringent
eligibility criteria. Patients who are largely excluded
from RCTs are more representative of the general
population and provide insights into baseline prognos-
tic factors, dosing strategies, management of adverse
events (AEs), and treatment effectiveness in real-world
settings. Early cardiotoxicity of doxorubicin remains a
severe medical concern in DLBCL patients receiving
the cyclophosphamide, doxorubicin, vincristine, and
prednisolone (CHOP) regimen [11]. Moreover, cardio-
vascular mortality in patients with lymphoma who
receive rituximab with CHOP (R-CHOP) was rela-
tively high, with approximately 30 % of deaths attrib-
uted to cardiovascular complications [12]. In addition
to cardiotoxicity, the FDA recently issued a warning
that patients receiving immune-suppressing rituximab
or ofatumumab are at an increased risk of hepatitis B
virus (HBV) reactivation [13]. Because HBV infection
is highly endemic in China, 12–27 % of all Chinese
patients with NHL are positive for hepatitis B surface
antigen (HBsAg), which increases the risk of HBV
reactivation [14–17]. HBV reactivation may increase
hepatic mortality and lead to interruption of curative
chemotherapy, which has a deleterious impact on
survival outcomes. Despite its clinical importance and
urgency, awareness, attitudes, and current screening
practices and preventive measures for HBV reactiva-
tion among physicians remain suboptimal [18, 19]. A
recent study in China reported HBV reactivation in
approximately 17.1 % of HBsAg-positive (pos) patients
receiving R-chemo [20].
This prospective, non-interventional study evaluated
the safety and effectiveness outcomes of R-chemo in
real-world clinical settings by including Chinese patients
aged ≤18 and >80 years and with history of cardiovascu-
lar and liver disease, who were largely excluded from
such RCTs. We also investigated HBV infection manage-
ment in patients with DLBCL.
Methods
Study design
Thismulticenter, single-arm, prospective, non-interventional
study is being conducted at 24 centers in China between
January 17, 2011 and October 31, 2016. Previously untreated
CD20-positive DLBCL patients who were eligible to receive
R-chemo (CHOP or non-CHOP) as first-line treatment were
enrolled with no specific exclusion criteria. The dose and
duration of treatment for each patient was determined at the
investigator’s discretion, in accordance with local labeling in-
formation (rituximab given at the dose of 375 mg/m2 body
surface area, once in three weeks) and standard clinical prac-
tice. The study was conducted according to the Chinese
guidelines for treatment of DLBCL, which was followed by
all study centers. Data for baseline characteristics were re-
trieved from medical records. For the present study, data
on safety, treatment effectiveness, and HBV infection man-
agement were collected from medical records 120 days after
the last rituximab dose administration.
The study protocols were approved by Institutional
Review Boards at each center. This study was performed
in accordance with Good Clinical Practice and ethical
principles of the Declaration of Helsinki. All patients
provided written informed consent. The study is regis-
tered at clinicaltrials.gov (NCT01340443). Additional
information on study procedures has been provided in
the Additional file 1.
Safety and effectiveness assessments
The safety endpoints included AEs, severe adverse
events (SAEs), adverse drug reactions (ADRs), and ad-
verse events of special interest (AESIs). The effective-
ness endpoints included overall response rate (ORR),
complete response (CR), unconfirmed CR (CRu), partial
response (PR), progression-free survival (PFS), and overall
survival (OS). ORR was defined as the proportion of
patients achieving CR, CRu or PR. Treatment response
was evaluated using standardized response criteria for
NHL [21]. Measurements for assessment were recorded
every 2 cycles. Computed tomography (CT) was used
to evaluate the lesions and was performed at the in-
vestigator’s discretion. The management of HBV was
evaluated, including diagnostic techniques for HBV in-
fection and liver function screening prior to R-chemo,
monitoring viral replication during and after R-chemo,
use of antiviral prophylaxis, and HBV reactivations.
Laboratory examinations were performed at the inves-
tigator’s discretion in accordance with local clinical
practice guidelines. This study reported the safety (AE,
SAE, AESI, and ADR) and short-term effectiveness of
R-chemo (ORR, CR, CRu, and PR) as well as the man-
agement of HBV infection within 120 days after the
last R dose administration.
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Statistical analysis
All DLBCL patients who received ≥1 dose of R-chemo
were included in the safety analysis populations. Patients
who received ≥1 dose of R-chemo and had undergone ≥1
tumor assessment after baseline were evaluable for effect-
iveness and were included in the intention-to-treat (ITT)
population. Descriptive statistics were used to summarize
baseline characteristics, HBV infection and replication,
and use of antiviral prophylaxis. Demographic data were
summarized as mean ± standard deviation for continuous
variables and as percentages for categorical variables. Re-
sponse rates were assessed by calculating percentages and
95 % confidence intervals (CIs) in the ITT population.
Categorical variables among subgroups were compared
using Fisher’s exact test. Logarithmic transformation was
performed for skewed data. Multivariate logistic regres-
sion was used to explore association between baseline
factors (International Prognostic Index [IPI], age, gender,
Eastern Cooperative Oncology Group [ECOG] score,
HBsAg/HBcAb, maximum tumor diameter, and history of
heart diseases) and treatment responses (CR +CRu and
CR), and p values <0.05 were considered statistically sig-
nificant. IPI is an ordered categorical variable categorized
as 1 for low risk, 2 for low-intermediate, 3 intermediate-
high, and 4 for high. Statistical analyses were conducted
using SAS version 9.2.
Results
Patient characteristics and treatment
Overall, the safety analysis population included 279 pa-
tients with DLBCL. Of these, 258 patients were included
in the ITT population, the main reason for exclusion
being lack of tumor assessment at baseline. Baseline
patient characteristics are summarized in Additional
file 1: Table S1.
Baseline characteristics of patients with history of heart
disease or liver diseases and patients without disease his-
tory are shown in Additional file 1: Table S2. Patients with
a history of heart disease were significantly older com-
pared to those without disease history (median age, 68 vs
56 years; p < 0.001).
Safety
In real-world clinical settings, R-chemo was generally
well tolerated as first-line treatment in Chinese patients
with DLBCL. The incidence of AEs was 95.7 % and the
incidence of grade 3–4 AEs, SAEs, AESIs, and ADRs
was 52.7, 16.8, 16.5, and 81.0 %, respectively (Table 1).
The most common AEs were low white blood cell count,
low neutrophil count, and nausea (Additional file 1:
Table S3). Most AEs were resolved through symptomatic
treatment, dose reduction, or discontinuation of treatment.
The incidence of AE-related deaths was 1.1 % (n = 3).
Of the 279 patients, 8 (2.9 %) patients discontinued
treatment, and 13 (4.7 %) reduced treatment dose due
to AEs (Table 2). Table 1 summarizes the age-stratified
incidence of AEs, SAEs, AESIs, and ADRs. The most
common AEs (any grade and grade 3–4) in patients
aged ≤18 or >80 years (n = 10) were low white blood
cell count and low neutrophil count (Data not shown).
As mentioned above, 67 patients enrolled in this study
had a history of heart or liver disease, characteristics that
would normally result in exclusion from RCTs. The inci-
dence of AEs in patients with history of heart or liver
diseases was similar to those without disease history
(Table 1). However, patients with a history of heart or
liver disease showed an increasing incidence of grade 3–4
AEs, SAEs, and AESIs compared to those without
(Table 1). The most common AEs (System Organ Class-
Preferred Terms [SOC-PT]) in patients with history of
heart diseases were low white blood cell count, anemia,
and nausea (Additional file 1: Table S3). The most
common AEs (SOC-PT) in patients with history of liver
diseases were low white blood cell count, low neutro-
phil count, and nausea (Additional file 1: Table S3).
Standardized MedDRA Queries (SMQs) were further
applied to identify hepatic and cardiovascular AEs occur-
ring in these patients. A summary of hepatic and cardio-
vascular AEs (SMQs) occurring in 5 % of the safety
analysis population and patients with a history of liver or
heart disease is presented in Additional file 1: Table S4
and Additional file 1: Table S5. The incidence of hepatic
AEs (SMQ) was 27.3 % (12/44) in patients with history
Table 1 Summary of AEs, SAEs, AESIs, and ADRs reported in patients receiving R-chemo
Baseline characteristics AE (any grade), n (%) AE (grade 3–4), n (%) SAE, n (%) AESI, n (%) ADR, n (%)
Total (n = 279) 267(95.7) 147(52.7) 47(16.8) 46 (16.5) 226 (81.0)
Age, y 19–60 (n = 160) 206 (95.8) 103 (47.9) 30 (14.0) 32 (14.9) 172 (80.0)
61–80 (n = 109) 22 (95.7) 16 (69.6) 7(30.4) 6 (26.1) 21(91.3)
≤18 to >80 (n = 10) 42 (95.5) 30 (68.2) 11(25.0) 9 (20.5) 36 (81.8)
History of diseases Heart diseases (n = 23) 10 (100.0) 5 (50.0) 3 (30.0) 2 (20.0) 10 (100.0)
Liver diseases (n = 44) 152 (95.0) 76 (47.5) 22 (13.8) 22 (13.8) 126 (78.8)
No heart or liver diseases (n = 215) 105 (96.3) 66 (60.6) 22 (20.2) 22 (20.2) 90 (82.6)
ADR adverse drug reaction, AE adverse event, AESI adverse event of special interest, chemo chemotherapy, SAE severe adverse event, R rituximab, y year
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of liver diseases and 22.6 % (63/279) in the safety analysis
population (Additional file 1: Table S4). In addition, the
incidence rate of cardiovascular AEs (SMQ) was 21.7 %
(5/23) in patients with history of heart diseases and 10.4 %
(29/279) in the safety analysis population (Additional file
1: Table S5). Grade 3–4 hepatic and cardiovascular AEs
were reported in 3.6 % (10/279) and 1.4 % (4/279) of the
safety analysis population, respectively. In patients with
disease history, grade 3–4 hepatic AEs were reported in 5
of 44 patients with a history of liver disease (11.4 %),
whereas grade 3–4 cardiovascular AEs were reported only
in 1 of 23 patients with a history of heart disease (4.3 %).
The safety profile was similar to that of the safety analysis
population, with no addition of unexpected safety con-
cerns. One cardiovascular-related death was reported in
the study, which was not related to the study treatment.
In order to determine whether AEs resulted in interrup-
tions of R-chemo treatment in patients with disease his-
tory, investigated the incidence of dose reduction and
treatment termination due to AEs (Table 2). Two of 23
patients with heart diseases and 5 of 44 patients with liver
diseases discontinued therapy due to AEs; one patient
with heart disease and 3 with liver diseases had dose
reductions due to AEs. The average dose of doxorubicin
was numerically lower in patients with heart diseases
than those without (79.3 ± 27.11 mg vs 87.5 ± 28.86 mg;
p = 0.303). The average treatment cycle was similar among
patients with a history of heart or liver disease and those
without disease history (5.9, 6.1, and 5.9, respectively).
R-chemo-treated patients with HBV infection
Different HBV infection statuses were defined according
to positivity of HBV serological markers (HBsAg and
hepatitis B core antibody [HBcAb]): HBsAg-pos group
represents patients with active HBV infections or inactive
carriers and HBsAg-negative (neg)/HBcAb-pos indicates
patients with resolved HBV infections. In this study, 242
(86.7 %) patients were tested for HBsAg and HBcAb prior
to DLBCL treatment; of these patients, 9.9 % (24/242) pa-
tients were HBsAg-pos, 28.5 % (69/242) were HBsAg-neg/
HBcAb-pos, and 61.6 % (149/242) were HBsAg/HBcAb
double-neg. For the other 37 patients, HBV infection sta-
tus at baseline was unknown. Moreover, HBV DNA levels
were evaluated at baseline in 70.8 % (17/24) of HBsAg-
pos, 44.9 % (31/69) of HBsAg-neg/HBcAb-pos, 18.8 %
(28/149) of HBsAg/HBcAb double-neg, and 16.2 % (6/37)
of unknown patients. Of these, 47.1 % (8/17) of HBsAg-
pos and 3.2 % (1/31) of HBsAg-neg/HBcAb-pos patients
were positive for HBV DNA (Additional file 1: Figure S1).
At baseline, most patients underwent liver function
tests, including alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), and total bilirubin (TBIL)
(Additional file 1: Table S6).
Table 3 presents data on use of antiviral prophylaxis
and monitoring of HBV infection. In total, 25/279
patients received antiviral prophylaxis. The proportions
of HBsAg-pos and HBsAg-neg/HBcAb-pos patients re-
ceiving antiviral prophylaxis were 70.8 % (17/24) and
10.1 % (7/69), respectively. One patient with unknown
HBV infection status also received antiviral treatment.
Most patients received antiviral treatment at the same
time as, or prior to, R-chemo. However, some patients
had already discontinued antiviral treatment by 120 days
after the last R-chemo dose administration. During R-
chemo treatment, HBV serological markers, HBV DNA,
and ALT levels were monitored at least once in 43.0,
25.8, and 94.3 % of patients, respectively (Additional file 1:
Figure S2). After the last R-chemo dose administration,
HBV serological markers, HBV DNA, and ALT levels
were monitored at least once in 11.1, 9.3, and 64.2 % of
patients, respectively (Additional file 1: Figure S2).
By the Consensus definition [22, 23], the incidence of
HBV reactivation in HBsAg-pos and HBsAg-neg/HBcAb-
pos patients was 12.5 % (3/24) and 4.3 % (3/69), respec-
tively. In contrast, investigators only reported 3 cases
of HBV reactivation based on their clinical experience:
one case each in HBsAg-neg/HBcAb-pos, double-neg,
and unknown patients.
Effectiveness
In this real-world clinical study, first-line R-chemo treat-
ment in Chinese patients with DLBCL resulted in an
ORR of 94.2 % (CR, 55.0 %; CRu, 18.2 %, and PR,
20.9 %). Next, we investigated treatment effectiveness in
patients with a history of heart or liver disease. Interest-
ingly, a higher proportion of patients with a history of
heart or liver disease achieved PR compared with those
without disease history (Fig. 1). In fact, the rate of PR in
patients with liver diseases was significantly higher than
in those without disease history (34.1 % vs 18.5 %, p =
0.035). In contrast, CR rates were lower in patients with
a history of heart or liver disease than in those without
Table 2 Dose reduction and treatment interruptions due to AEs
Treatment interruption Total
(n = 279), n (%)
No history of heart or liver
diseases (n = 215), n (%)
History of heart
diseases (n = 23), n (%)
History of liver diseases
(n = 44), n (%)
p value* p value**
Dose reduction 13 (4.7) 9 (4.2) 1 (4.3) 3 (6.8) 1.000 0.435
Treatment discontinuation 8 (2.9) 2 (0.9) 2 (8.7) 5 (11.4) 0.048 0.002
*Patients without history of heart or liver diseases were compared with those with history of heart diseases using Fisher’s exact test, and p values were obtained
**Patients without history of heart or liver diseases were compared with those with history of liver diseases using Fisher’s exact test, and p values were obtained
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Fig. 1 Treatment effectiveness of R-chemo in patients with a history of heart or liver disease (Patients who received ≥1 dose of R-chemo and
underwent ≥1 tumor assessments after baseline were included in the analysis chemo, chemotherapy; CR, complete response; CRu, complete
response unconfirmed; PR, partial response; ORR, overall response rate; R, rituximab)
Table 3 Use of antiviral prophylaxis and HBV infection management in DLBCL patients receiving R-chemo








HBsAb positivity, n (%) 3 (12.5) 53 (76.8) 58 (38.9) 1 (2.7)
Antiviral prophylaxis
Received antiviral prophylaxis, n (%) 17 (70.8) 7 (10.1) 0 (0.0) 1 (2.7)
Median number of cycles administered when prophylaxis was initiated (range)
Time started with prophylaxis relative to R-Chemo (range) 1 (1, 1) 1 (1, 1) – 1 (1, 1)
Stopped prophylaxis by 120 d after last R dose, n (%)
Antiviral treatment duration, day (range) −1 (–20, 2)1 0 (−1, 0) – −4 (−4, −4)
4 (16.7) 3 (4.3) – 0
9 (4–12)1 6 (1–185) – –
Monitored for serologic markers,2 n (%) 14 (58.3) 36 (52.2) 68 (45.6) 2 (5.4)
Median interval, day (range) 53.7 (25–205) 37.0 (18–291) 35.3 (21–315) 24.0 (21–27)
First check after R-chemo, day (range) 26.0 (1–34) 23.0 (1–61) 19.0 (1–90) 20.0 (20–20)
Monitored for HBV DNA,3 n (%) 18 (75.0) 21 (30.4) 15 (10.1) 7 (18.9)
Median interval, d (range) 34.9 (22–267) 35.6 (21–168) 40.8 (21–136) 40.0 (22–143)
First check after R-chemo, d (range) 21.5 (1–49) 24.0 (1–61) 4.0 (1–25) 21.0 (20–122)
Monitored for liver function,4 n (%) 23 (95.8) 65 (94.2) 144 (96.6) 37 (100)
Median interval, d (range) 29.9 (20–48) 29.2 (21-51) 28.4 (4–82) 29.0 (15–61)
First check after R-chemo, d (range) 26.5 (20–9) 34.0 (8–114) 25.0 (1–117) 22.0 (1–120)
1Information on use of antiviral prophylaxis was missing for one subject and was thus not included in the analysis
2HBsAg and HBeAg levels were monitored at least twice in the study, including at baseline
3HBV DNA was monitored at least twice, including at baseline
4ALT levels were monitored at least twice, including at baseline
chemo, chemotherapy; DLBCL, diffuse large B-cell lymphoma; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface
antigen; HBV, hepatitis B virus; neg, negative; pos, positive; R, rituximab
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disease history (47.4 % vs 57.5 %, p = 0.470; 43.9 % vs 57.5,
p = 0.123) (Fig. 1).
To investigate the prognostic factors of treatment,
baseline factors were examined. IPI, age, gender, ECOG
score, HBsAg/HBcAb, maximum tumor diameter, and
history of heart diseases were tested.. HBsAg positivity
(p = 0.0017; OR < 1) and tumor diameter of ≥7.5 cm (p =
0.02; OR < 1) had a negative correlation with CR + CRu
(Fig. 2a). In addition, age (p = 0.01; OR < 1) or HBsAg
positivity (p = 0.02; OR < 1) was associated with a reduced
likelihood of achieving CR (Fig. 2b). Other baseline factors,
such as age, gender, ECOG, HBsAg negativity/HBcAb
positivity, or history of heart diseases, were not predictive
of CR +CRu or CR.
Consistent with the multivariate analyses results, the
rates of CR and CRu were numerically lower in HBsAg-
pos patients than in HBsAg/HBcAb double-neg patients
(40.9 % vs 58.3 %, p = 0.166; 13.6 % vs 18.7 %, p = 0.768)
(Fig. 3). In contrast, PR rates were higher in HBsAg-pos
patients compared with double-neg patients (40.9 % vs
19.4 %, p = 0.050). Further comparisons of baseline factors
showed a significant difference in ECOG performance
scores between HBsAg-pos patients and double-neg
patients (p = 0.04; Additional file 1: Table S7). The pro-
portion of HBsAg-pos patients presenting with ECOG
scores of 0, 1, 2, and 3 were 9.1, 72.7, 13.6, and 4.5 %,
respectively. The median number of treatment cycles
was significantly higher in HBsAg-pos patients than in
HBsAg/HBcAb double-neg patients (7.5 vs.6.0; p = 0.045).
Discussion
In this real-world clinical study, R-chemo was generally
well tolerated in Chinese patients with DLBCL, which
further validates the tolerability of R-chemo seen in
landmark rituximab trials. The safety profile was well
described without unexpected toxicities. Most AEs were
resolved through symptomatic treatment, dose reduction,
or R-chemo treatment discontinuation. The proportion of
Fig. 2 Multivariate logistic regression analyses of prognostic factors. Baseline factors were examined using multivariate logistic regression analyses
to investigate prognostic factors of treatment responses. The baseline factors included IPI, age, HBsAg positivity, HBsAg negativity/HBcAb
positivity, and maximum tumor diameter. IPI is an ordered categorical variable categorized as 1 for low risk, 2 for low-intermediate, 3
intermediate-high, and 4 for high. a Baseline prognostic factors correlated with CR + CRu. b Baseline prognostic factors correlated with
the likelihood of achieving CR. CR, complete response; CRu, complete response unconfirmed
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AE-related death was 1.1 %. First-line treatment with R-
chemo in Chinese patients with DLBCL resulted in an
ORR of 94.2 % (CR, 55.0 %; CRu, 18.2 %; and PR, 20.9 %).
This is in line with ORRs reported in other studies con-
ducted in Chinese patients [10, 24]. The CR rates were
similar between Chinese and Western patients [6]. In a
study including Westerners, 8 cycles of R-CHOP treat-
ment produced an ORR of 82.7 % (CR, 52.5 %; CRu,
22.8 %, and PR, 7.4 %) [6], though all patients were aged
60-80 years, 46.0 % had low or low-intermediate risk
based on IPI scores and 38.6 % patients had B symptoms.
In the present study, Chinese patients with DLBCL tended
to be younger (59.7 % patients with age ≤60 years), have
low or low-intermediate risk per IPI scores (76.4 %), and
fewer patients presented with B symptoms (19.0 %).
In this study, 67 patients had a history of heart or liver
disease (23 and 44, respectively), which were the most
commonly observed diseases in the patient medical
histories. R-chemo was generally well tolerated in these
patients; only two patients with heart diseases and five
patients with liver diseases discontinued treatment due
to AEs. Despite the fact that the incidence of hepatic
and cardiovascular AEs was higher in these patients, the
safety profile was similar to that of the safety analysis
population, with no unexpected toxicities. Interestingly,
these patients achieved a higher ORR than those without
a history of heart or liver disease. However, these patients
had a tendency to achieve PR instead of CR. CR rates were
numerically lower in patients with a history of heart or
liver disease than in those without. This tendency may be
partially attributed to the intrinsic baseline characteristics
of these patients and treatment interruptions.
Patients with a history of heart disease (n = 23) were
older than those without a history of heart or liver
disease (68 vs 56 years; p < 0.001). The average dose of
doxorubicin was numerically lower in patients with
heart diseases than in those without (79.3 vs 87.5 mg).
Patients with history of heart diseases could further
benefit from R-chemo if preventative measures are taken
to reduce cardiovascular toxicity.
A total of 44 patients had history of liver diseases, with
a significant proportion of patients positive for HBsAg
(n = 24). In comparison with HBsAg/HBcAb double-neg
patients, HBsAg-pos patients achieved lower rates of CR
and CRu but significantly higher rates of PR. Moreover,
multivariate analyses demonstrate that HBsAg positivity
was associated with a reduced likelihood of achieving
CR. The tendency of achieving significantly higher PR
in HBsAg-pos patients versus double-neg patients was
unlikely to be due to inadequate treatment because
HBsAg-pos patients received a higher number of R-
chemo cycles compared to HBsAg/HBcAb double-neg
patients. On the other hand, patients with other HBV
infection status (HBsAg-neg/HBcAb-pos) showed simi-
lar treatment responses as HBsAg/HBcAb double-neg
patients. The mechanism of the negative association
between HBsAg and outcomes could be explained in
part by the differences in disease presentation. Previous
studies have shown that HBsAg-pos patients usually
presented with earlier onset and more advanced stages
of DLBCL [25]. Indeed, patients reported here showed
significantly different presentation of ECOG scores be-
tween HBsAg-pos and other groups. Approximately
90.9 % of HBsAg-pos patients presented with ECOG
Fig. 3 Treatment effectiveness of R-chemo in patients with HBV infectious status (Patients who received ≥1 dose of R-chemo and underwent ≥1
tumor assessment after baseline were included in the analysis chemo, chemotherapy; CR, complete response; CRu, complete response unconfirmed;
PR, partial response; ORR, overall response rate; R, rituximab)
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scores ranging 1–3 in contrast to 66.9 % in HBsAg/
HBcAb double-neg patients. Consistent with our find-
ings, a recent retrospective study also identified HBsAg
positivity as an important risk factor for overall survival of
patients with DLBCL receiving R-chemo treatment [26];
in this study, patients with different HBV infection sta-
tuses achieved similar outcomes in the CHOP group.
However, HBsAg-pos patients in the R-CHOP group
presented with unfavorable long-term outcomes com-
pared with uninfected patients and HBsAb-neg/HBcAb-
pos patients [26]. Nevertheless, the same study also
demonstrated the advantages of R-CHOP over CHOP
in treating HBsAg-pos patients; the CR rates were
80.0 % (16/20) for HBsAg-pos patients receiving R-
CHOP and 69.4 % (25/36) for those receiving CHOP, in-
dicating benefit of R-CHOP over CHOP in HBsAg-pos
patients. However, these findings should be interpreted
with caution considering the nature of observational
studies and the small sample size. Patients with a history
of liver disease, particularly those positive for HBsAg, may
further benefit from R-chemo treatment if HBV infection
is appropriately managed to reduce hepatic toxicity.
Additional studies are warranted to verify the safety
and effectiveness of R-chemo in such patients and seek
optimal management and treatment regimens. In addition,
the present study examined the management of HBV
infection in Chinese DLBCL patients in real-world
settings. Although it has been established that HBV re-
activation in patients receiving chemotherapy can be
effectively prevented by the use of antiviral prophy-
laxis, there remain several unmet needs that hinder
optimal management of HBV infection in DLBCL pa-
tients. Our study found that most Chinese physicians
acknowledged the importance of HBV screening before
the initiation of R-chemo. However, improvements in
HBV infection monitoring and antiviral treatment are
required. Even with monitoring, physicians do not con-
sistently define HBV reactivation, which may lead to
underreporting of reactivation, as observed in the present
study. Therefore, long-term monitoring is warranted for
such patients, particularly after discontinuing antiviral
treatment to delay HBV reactivation.
As with observational studies, one of the most significant
limitations of the present study was limited availability of
data from real-life clinical settings. Observational studies
are useful to validate findings from RCTs and draw infer-
ences regarding the safety and effectiveness of treatment
but not scientifically capable of proving or disproving hy-
potheses [27–29]. In addition, the number of very young/
old patients and patients with heart or liver diseases in
this study were relatively small. Additional studies are
warranted to verify these findings. Last, the current study
only analyzed safety and effectiveness 120 days after the
last dose of rituximab. No study has reported the long-
term safety and effectiveness of R-chemo in Chinese
patients with DLBCL.
Conclusions
The results from this study show that the effectiveness
and tolerability of R-chemo in real-life clinical practice
are in line with those reported in large RCTs. Of note,
this study suggests that patients with heart or liver dis-
eases could further benefit from R-chemo if preventative
measures are taken to reduce hepatic and cardiovascular
toxicity. In addition, this study provides some insights
into treatment responses and prognostic factors in Chinese
patients with DLBCL. Moreover, HBsAg positivity appeared
to be a negative prognostic factor in such patients.
Additional studies are warranted to optimize treatment
and management strategies in such patients.
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